Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Tenax Therapeutics (NASDAQ: TENX), a Phase 3 development-stage pharmaceutical company focused on cardiopulmonary therapies, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The conference will be held virtually from April 7-10, 2025. The company's corporate presentation is scheduled for April 7, 2025, at 3:45 p.m. ET. Key participants include Chris Giordano (President & CEO), Dr. Stuart Rich (Chief Medical Officer), and Doug Randall (Chief Business Officer).

Both live and archived versions of the presentation will be available through the company's investor relations webpage.

CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the 24^th Annual Needham Virtual Healthcare Conference, which is taking place virtually from April 7-10, 2025.

Details of presentation:

Format: Corporate Presentation

Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer, Doug Randall, Chief Business Officer

Date and Time: April 7, 2025, at 3:45 p.m. ET

The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.

About Tenax Therapeutics

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.

Contact:

Investor and Media:

Merrill Barrett
Argot Partners
tenax@argotpartners.com

FAQ

When is Tenax Therapeutics (TENX) presenting at the Needham Healthcare Conference 2025?

Tenax Therapeutics (TENX) will present on April 7, 2025, at 3:45 p.m. ET during the 24th Annual Needham Virtual Healthcare Conference.

Who are the key executives presenting at TENX's Needham Conference presentation?

Chris Giordano (President & CEO), Dr. Stuart Rich (Chief Medical Officer), and Doug Randall (Chief Business Officer) will participate in the corporate presentation.

How can investors access TENX's Needham Conference presentation?

Investors can access both the live and archived webcast of the presentation through Tenax Therapeutics' investor relations webpage.

What is the current development stage of Tenax Therapeutics (TENX)?

Tenax Therapeutics is a Phase 3 development-stage pharmaceutical company developing novel cardiopulmonary therapies.